Top Partnering Opportunities: Finding Targets Off The Beaten Path
Competition is fierce among companies seeking to out-license candidates to big pharmas. Upcoming Therapeutic Area Partnerships meeting aims to highlight those assets with best chances of attracting partners. Rare diseases continue to be an area rich in innovation and investment.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.